Angel Adegbesan
Merck & Co. said U.S. regulators declined to approve the company’s application for its experimental chronic-cough drug in its current form, a setback as the drugmaker seeks new potential blockbusters.
The U.S. Food and Drug Administration sent Merck a complete response letter requesting additional information regarding the measurement of efficacy of the medication, gefapixant, according to a statement on Monday from the Kenilworth, New Jersey-based company. Merck said the agency’s decision wasn’t related to the safety of the drug.
